Product Description
Crisantaspase is an asparaginase enzyme produced by Erwinia chrysanthemi and used to treat acute lymphoblastic leukemia (ALL) in case of hypersensitivity to Escherichia coli l-asparaginase (ASNase). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30597637/)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous, Intramuscular
FDA Designation: Fast Track - Pancreatic Cancer *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: ERYtech Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Common Cold|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: B-Cell Leukemia|Burkitt Lymphoma|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia
Phase 1: Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04292743 |
STUDY00002008 | P1 |
Completed |
Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma |
2023-01-18 |
21% |
2025-02-15 |
|
NCT06738368 |
RG1124788 | P2 |
Not yet recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|T-Cell Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Burkitt Lymphoma |
2028-01-31 |
12% |
2025-12-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT03156790 |
MC-Spectrila.1/ALL | P2 |
Active, not recruiting |
B-Cell Leukemia|Acute Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell |
2025-04-29 |
2% |
2025-08-23 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
NCT04043494 |
LBL 2018 | P3 |
Recruiting |
Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin |
2027-11-22 |
2024-11-27 |
||
NCT03117751 |
TOT17 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-09-30 |
10% |
2024-11-27 |
Primary Endpoints|Treatments |
ACTRN12621000604808p |
2006-7041-83/hah | P3 |
Not yet recruiting |
Common Cold |
2021-10-29 |
|||
ACTRN12623000491662 |
ACTRN12623000491662 | P1 |
Not yet recruiting |
Acute Lymphoid Leukemia |
2023-07-31 |
2024-08-29 |
Treatments|Trial Status |
|
NCT03020030 |
NCT03020030 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-11-30 |
50% |
2025-01-04 |
|
2012-000793-30 |
IntReALL SR 2010 | P3 |
Completed |
Acute Lymphoid Leukemia |
2024-04-25 |
2025-05-06 |
Treatments |
|
NCT05848687 |
TINI 2 | P2 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Leukemia |
2028-12-01 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT03643276 |
AIEOP-BFM ALL 2017 | P3 |
Recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2028-07-14 |
2024-11-27 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/17/2025 |
News Article |
CalciMedica Announces Presentations at Upcoming Medical Meetings |
|
04/01/2025 |
News Article |
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference |
|
03/05/2025 |
News Article |
CalciMedica Secures Credit Facility for Up to $32.5 Million |
|
02/19/2025 |
News Article |
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference |